Screening of Therapeutic Targets for Pancreatic Cancer by Bioinformatics Methods

Abstract

Pancreatic cancer (PC) has the lowest survival rate and the highest mortality rate among all cancers due to lack of effective treatments. The objective of the current study was to identify potential therapeutic targets in PC. Three transcriptome datasets, namely GSE62452, GSE46234, and GSE101448, were analyzed for differentially expressed genes (DEGs) between cancer and normal samples. Several bioinformatics methods, including functional analysis, pathway enrichment, hub genes, and drugs were used to screen therapeutic targets for PC. Fisher’s exact test was used to analyze functional enrichments. To screen DEGs, the paired t-test was employed. The statistical significance was considered at p <0.05. Overall, 60 DEGs were detected. Functional enrichment analysis revealed enrichment of the DEGs in “multicellular organismal process”, “metabolic process”, “cell communication”, and “enzyme regulator activity”. Pathway analysis demonstrated that the DEGs were primarily related to “Glycolipid metabolism”, “ECM-receptor interaction”, and “pathways in cancer”. Five hub genes were examined using the protein-protein interaction (PPI) network. Among these hub genes, 10 known drugs targeted to the CPA1 gene and CLPS gene were found. Overall, CPA1 and CLPS genes, as well as candidate drugs, may be useful for PC in the future.

Key words

pancreatic cancer - differentially expressed genes - targets - bioinformatics - treatment

Introduction

Pancreatic cancer (PC), a common tumor of the gastrointestinal tract, has a poor survival rate [1]. This is primarily because PC is hidden on the posterior side of the right upper abdomen [2]. Patients may be unaware of the initial symptoms such as upper abdominal discomfort, weight loss, yellowing of the skin, fatigue, and cognitive issues, making them easily overlooked. Moreover, the lack of precise biomarkers for PC aggravates the issue [3]. Lack of effective treatments are the second reason for poor survival rate. Various treatments such as surgery, radiotherapy, and chemotherapy are typically utilized. Nevertheless, those who have undergone surgery have a high chance of relapse, and are not as responsive to radiation or chemotherapy treatments [4]. Resultantly, more effective biomarkers or novel treatments for PC are warranted.

Bioinformatics methods have been used in numerous diseases, including cancers [5] [6] [7], further providing novel insights into cancer. A few bioinformatics studies could examine only one gene associated with PC [8] [9] [10]. Tumors are not exclusively caused by a single gene, but rather are the result of several genetic factors combined. Moreover, the above studies ignored targeted drugs for cancer. Hence, the diagnosis and management of PC is a difficult task and its comprehensive exploration has attracted intense curiosity.

Novel uses of earlier drugs can be a revolutionary development [11]. Drugs for non-cancerous have the potential to treat cancer. For instance, statins used for patients undergoing heart failure treatment have demonstrated anti-tumor activity [12] [13] [14]. Aspirin, an antiplatelet drug, has shown anti-tumor effects as well [15] [16] [17]. Hence, it is hypothesized that some existing drugs could be useful in the treatment of PC.

The objective of the current study was to identify target genes and drugs in PC using several bioinformatical methods. First, three pooled datasets were selected from the Gene Expression Omnibus (GEO) database. Second, differentially expressed genes (DEGs) were detected between PC patients and healthy individuals. Next, these DEGs were analyzed using several bioinformatics methods. Finally, the potential biomarkers and drugs targeted to PC were identified. Expectedly, the present study may offer a promising treatment for PC.

Materials and Methods

Data summary

Gene Expression Omnibus (GEO) database stores microarray and high-throughput gene expression data [18]. Three datasets, namely GSE62452, GSE46234, and GSE101448, were obtained from GPL6244, GPL570, and GPL10558 platforms, respectively, in the GEO database. GSE62452 had 61 cancer and 69 normal tissues; GSE46234 comprised four cancer and four normal samples; GSE101448 showed 19 cancer and 24 normal samples (Supplement [Table 1S]) .

Table 1 List of the differentially expressed genes (DEGs).

Term	Gene name
Upregulated genes	KIAA1324, CELA3A, CEL, EGF, AQP8, CLPS, TRHDE, CPB1, GP2, PDK4, RBPJL, PRSS3P2, PDIA2, CTRC, IAPP, PLA2G1B, CELA3B, ERP27, CELA2B, ERP44, CTRL, TMED6, ALB, AOX1, F11, CPA2, REG1B, PNLIPRP2, CPA1, NR5A2, PNLIPRP1, KLK1, SERPINI2
Downregulated genes	SERPINB5, CEACAM6, COL1A1, FN1, LAMB3, DPCR1, SLPI, NOX4, CDH11, ITGA2, SLC6A14, COL3A1, ANXA10, POSTN, CEACAM5, TMC5, CTSE, GABRP, THBS2, KRT19, SULF1, LAMC2, AHNAK2, TFF1, CLDN18, CP, AGR2

Ethics statement

As the data were re-analyzed from the public dataset, no ethical approval by the local ethics committee was necessary.

DEGs identification

GEO2R, an interactive web tool, was employed to identify the DEGs between PC and normal specimens [19]. The upregulated DEGs are logFC >1 and p <0.05. The opposite logFC are the downregulated DEGs. Venn diagram tool (http://bioinformatics.psb.ugent.be/webtools/Venn/) was applied to obtain common DEGs.

Functional and pathway enrichment analysis

Database for Annotation, Visualization, and Integrated Discovery (DAVID), an online bioinformatics tool, was used for Gene ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses [19].

Protein-protein interaction (PPI) network

To establish an association among the DEGs and construct the PPI network, the Search Tool for the Retrieval of Interacting Genes (STRING, http://string-db.org) was applied [20]. Subsequently, Cytoscape version 3.7.2 was used to visualize the PPI network. The MCODE (Molecular Complex Detection) plugin from Cytoscape analyzed the hub genes [21].

Drug screening

The Drug Gene Interaction Database (DGIdb) (https://www.dgidb.org) was used to search for drugs associated with hub genes.

Statistics analysis

Fisher’s exact test was employed to evaluate functional enrichments. The t-test was applied to screen DEGs. A value of p <0.05 indicated statistical significance.

Results

DEGs Identification

Venn diagram depicts 60 genes, including 33 upregulated ([Fig. 1a]) and 27 downregulated genes ([Fig. 1b]) overlapping among three datasets. [Table 1] lists the names of DEGs.

Fig. 1 The common differentially expressed genes (DEGs) in GSE62452, GSE46234, and GSE101448. a: The common 33 upregulated DEGs. b: The common 27 downregulated DEGs.

Functional enrichment analysis

For functional enrichment, biological process (BP) terms were clustered in the “multicellular organismal process”, “biological regulation”, “cell communication”, “response to stimulus”, and “metabolic process”. Besides, cellular component (CC) terms were associated with “endomembrane system”, “extracellular space”, “vesicle”, “membrane” and “protein-containing complex”. In Molecular Function (MF) annotation, functional enrichment was associated with “hydrolase activity”, “structural molecule”, “protein binding”, “ion binding,” and “enzyme regulator” ([Fig. 2]). KEGG pathway revealed enrichment in “small cell lung cancer”, “glycolipid metabolism”, “ECM-receptor interaction”, “pathways in cancer”, and “focal adhesion” ([Table 2]).

Fig. 2 Functional analysis for differentially expressed genes.

Table 2 Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of the differentially expressed genes (DEGs).

Gene	Description	p-Value
hsa04512	ECM-receptor interaction	7.55E-07
hsa04510	Focal adhesion	9.85E-06
hsa05222	Small cell lung cancer	0.004666
hsa00561	Glycerolipid metabolism	0.014453
hsa05200	Pathways in cancer	0.0425

The construction of PPI

Forty-eight genes and 145 edges were clustered in the PPI network ([Fig. 3a]). Top genes were selected via the MCODE plugin. [Fig. 3b] shows nine top genes (CLPS, CELA3B, CPA2, CELA3A, CPA1, CPB1, CTRC, CTRL, and PRSS3P2).

Fig. 3 The protein-protein interaction (PPI) network and hub genes analysis. a: The PPI networks for differentially expressed genes. b: The top 9 genes in the PPI networks. Red nodes indicate upregulated genes; blue nodes indicate downregulated genes.

Screening the drugs

The top nine genes were employed to find drugs. CPA1 and CLPS genes matched with 10 drugs ([Table 3]). In the KEGG pathway, these genes were associated with the “fat digestion and absorption pathway”, “pancreatic secretion” and “protein digestion and absorption” ([Fig. 4] ).

Fig. 4 Screening drugs for hub genes. a: The potential drugs targeted the CPA1 and CLPS. b: The pathway associated with CPA1 and CLPS genes.

Table 3 The known drugs associated with CAP1 and CLPS genes.

Drug ID	Drug name	p-Value
DB04058	d-[(Amino)carbonyl]phenylalanine	0.001036
DB03441	2-Benzyl-3-iodopropanoic Acid	0.001142
DB04316	d-(N-Hydroxyamino)carbonyl]phenylalanine	0.001628
DB08222	Methoxyundecylphosphinic Acid	0.001753
DB04233	(Hydroxyethyloxy)tri(ethyloxy)octane	0.002442
DB06924	(2 R)-2-Benzyl-3-nitropropanoic acid	0.002850
DB03012	Phenylalanine-N-sulfonamide	0.003800
DB02451	B-Nonylglucoside	0.00455
DB03201	d-Cysteine	0.00570
DB02494	α-Hydroxy-β-phenylpropionic Acid	0.00995

Discussion

PC has the highest mortality and lowest survival rates of all cancers due to its difficulty to be detected in the early stages and the lack of effective treatments. Therefore, identifying biomarkers to diagnose or treat PC becomes urgent. Data sequencing can reveal the underlying diagnostic and prognostic mechanisms of different diseases, especially cancer. The development of related medications has opened up a new way to examine cancer and hypothesize about its molecular causes.

In this study, GSE62452, GSE46234, and GSE101448 datasets were analyzed for DEGs between abnormal and normal tissues. Sixty DEGs were screened. BP terms were clustered in the “multicellular organismal process”, “biological regulation”, “cell communication”, “response to stimulus”, and “metabolic process”. Further, CC terms were associated with “endomembrane system”, “extracellular space”, “vesicle”, “membrane”, and “protein-containing complex”. MF annotation revealed an association with “hydrolase activity”, “structural molecule”, “protein binding”, “ion binding” and “enzyme regulator”. In the KEGG pathway, PC was enriched in “small cell lung cancer”, “glycolipid metabolism”, “ECM-receptor interaction”, “pathways in cancer”, and “focal adhesion”. These results revealed an association of abnormal lipid metabolism with PC. Numerous research papers have established a link between lipid metabolism disorders and PC, in agreement with our results [22] [23] [24].

A total of 48 genes with 145 edges were included in the PPI part. Thereafter, hub genes were selected by the MCODE algorithm. Nine top genes, namely CLPS, CELA3B, CPA2, CELA3A, CPA1, CPB1, CTRC, CTRL, and PRSS3P2 were employed to identify drugs. CPA1 and CLPS genes matched with 10 drugs. In the KEGG pathway, these genes showed association with "pancreatic secretion”, “protein digestion and absorption”, and “fat digestion and absorption pathway”.

The protein encoded by the co-enzyme colipase (CLPS), a cofactor for efficient dietary lipid hydrolysis, performs tissue-specific regulation of expression in pancreatic alveolar cells [25] [26]. CLPS is key to the development and progression of PC and is a likely target for treatment [27]. Furthermore, CLPS has been reported to contribute to type 2 diabetes development [28].

Carboxypeptidase A1 (CPA1), a zinc metalloprotease produced by pancreatic alveolar cells, plays a vital role in the cleavage of C-terminal branched chains from dietary proteins [29]. When comparing the differentiating marker between normal and neoplastic pancreatic alveolar cells, CPA1 displays high sensitivity [29] [30]. Besides, the CPA1 variant aggravates the risk of chronic pancreatitis [31]. Hence, CLPS and CPA1 genes were associated with PC. We found 10 medications that have been given the green light by the FDA, which could potentially be useful in treating PC, and are specifically targeted at CLPS and CPA1 genes.

Conclusion

Overall, CPA1 and CLPS genes as well as candidate drugs were identified by bioinformatics methods in this study. This study may offer a novel idea for the diagnosis and treatment of PC.

Author Contributions

(I) Conception and design: Zhang Hongjian; (II) Administrative support: Wan Zheng; (III) Provision of study materials: Xiao Xiaojie; (IV) Collection and assembly of data: Xiao Xiaojie, Liu Xinmei, Chen Huaying, and Zhao Xiaoyan; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Conflict of Interest

The authors declare that they have no conflict of interest.

Acknowledgements

This study was supported by Natural Science Foundation of Fujian Province (Grant NO.2022J05298).

• References

• 1 Raimondi S, Maisonneuve P, Lowenfels AB.. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009; 6: 699-708
• 2 Ansari D, Tingstedt B, Andersson B. et al. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol 2016; 12: 1929-1946
• 3 Vincent A, Herman J, Schulick R. et al. Pancreatic cancer. Lancet 2011; 378: 607-620
• 4 Mizrahi JD, Surana R, Valle JW. et al. Pancreatic cancer. Lancet 2020; 395: 2008-2020
• 5 Parola C, Neumeier D, Reddy ST.. Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering. Immunology 2018; 153: 31-41
• 6 Reuter JA, Spacek DV, Snyder MP.. High-throughput sequencing technologies. Mol Cell 2015; 58: 586-597
• 7 Liang W, Zhao Y, Huang W. et al. Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). Theranostics 2019; 9: 2056-2070
• 8 Feng Y, Jiang Y, Hao F.. GSK2126458 has the potential to inhibit the proliferation of pancreatic cancer uncovered by bioinformatics analysis and pharmacological experiments. J Transl Med 2021; 19: 373
• 9 Wu J, Li Z, Zeng K. et al. Key genes associated with pancreatic cancer and their association with outcomes: A bioinformatics analysis. Mol Med Rep 2019; 20: 1343-1352
• 10 Jiang PF, Zhang XJ, Song CY. et al. S100P acts as a target of miR-495 in pancreatic cancer through bioinformatics analysis and experimental verification. Kaohsiung J Med Sci 2021; 37: 562-571
• 11 Kale VP, Habib H, Chitren R. et al. Old drugs, new uses: drug repurposing in hematological malignancies. Semin Cancer Biol 2021; 68: 242-248
• 12 Chapman-Shimshoni D, Yuklea M, Radnay J. et al. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 2003; 31: 779-783
• 13 Cho SJ, Kim JS, Kim JM. et al. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 2008; 123: 951-957
• 14 Lin JJ, Ezer N, Sigel K. et al. The effect of statins on survival in patients with stage IV lung cancer. Lung Cancer 2016; 99: 137-142
• 15 Ma J, Cai Z, Wei H. et al. The anti-tumor effect of aspirin: what we know and what we expect. Biomed Pharmacother 2017; 95: 656-661
• 16 Liu H, Xiong C, Liu J. et al. Aspirin exerts anti-tumor effect through inhibiting Blimp1 and activating ATF4/CHOP pathway in multiple myeloma. Biomed Pharmacother 2020; 125: 110005
• 17 Dai X, Yan J, Fu X. et al. Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase. Clin Cancer Res 2017; 23: 6267-6278
• 18 Clough E, Barrett T.. The gene expression omnibus database. Methods Mol Biol 2016; 1418: 93-110
• 19 Zeng X, Shi G, He Q. et al. Screening and predicted value of potential biomarkers for breast cancer using bioinformatics analysis. Sci Rep 2021; 11: 20799
• 20 Deng JL, Xu YH, Wang G.. Identification of potential crucial genes and key pathways in breast cancer using bioinformatic analysis. Front Genet 2019; 10: 695
• 21 Chen S, Yang D, Lei C. et al. Identification of crucial genes in abdominal aortic aneurysm by WGCNA. Peer J 2019; 7: e7873
• 22 Rozeveld CN, Johnson KM, Zhang L. et al. KRAS controls pancreatic cancer cell lipid metabolism and invasive potential through the lipase HSL. Cancer Res 2020; 80: 4932-4945
• 23 Sunami Y, Rebelo A, Kleeff J.. Lipid metabolism and lipid droplets in pancreatic cancer and stellate cells. Cancers (Basel) 2017; 10
• 24 Patra KC, Kato Y, Mizukami Y. et al. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol 2018; 20: 811-822
• 25 Sugar IP, Mizuno NK, Momsen MM. et al. Regulation of lipases by lipid-lipid interactions: implications for lipid-mediated signaling in cells. Chem Phys Lipids 2003; 122: 53-64
• 26 Xiao X, Ferguson MR, Magee KE. et al. The Arg92Cys colipase polymorphism impairs function and secretion by increasing protein misfolding. J Lipid Res 2013; 54: 514-521
• 27 Zhang G, He P, Tan H. et al. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res 2013; 19: 4983-4993
• 28 Weyrich P, Albet S, Lammers R. et al. Genetic variability of procolipase associates with altered insulin secretion in non-diabetic Caucasians. Exp Clin Endocrinol Diabetes 2009; 117: 83-87
• 29 Uhlig R, Contreras H, Weidemann S. et al. Carboxypeptidase A1 (CPA1) Immunohistochemistry is highly sensitive and specific for acinar cell carcinoma (ACC) of the pancreas. Am J Surg Pathol 2022; 46: 97-104
• 30 Kemik O, Kemik AS, Sumer A. et al. Serum procarboxypeptidase A and carboxypeptidase A levels in pancreatic disease. Hum Exp Toxicol 2012; 31: 447-451
• 31 Witt H, Beer S, Rosendahl J. et al. Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet 2013; 45: 1216-1220

Publication History

Received: 05 December 2022

Accepted after revision: 21 December 2022

Accepted Manuscript online:
04 January 2023

Article published online:
10 February 2023